EUVIMEDEUVIMED entdecken
Crossref

Cost-Effectiveness of Idelalisib-Rituximab for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia

Monia Marchetti

Haematology International Journal · 2017

DOI: 10.23880/hij-16000106 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haematology International Journal, 2017. Verfasst von Monia Marchetti.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Marchetti, M. (2017). Cost-Effectiveness of Idelalisib-Rituximab for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia. Haematology International Journal. https://doi.org/10.23880/hij-16000106

Vancouver

Marchetti M. Cost-Effectiveness of Idelalisib-Rituximab for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia. Haematology International Journal. 2017. doi:10.23880/hij-16000106

BibTeX
@article{Marchetti2017,
  author = {Marchetti, Monia},
  title = {Cost-Effectiveness of Idelalisib-Rituximab for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia},
  journal = {Haematology International Journal},
  year = {2017},
  doi = {10.23880/hij-16000106}
}
Kostenlos starten →